7 Januar 2010 | Case stories
NNIT has created succesful Quality Center solutions for both Lundbeck and Novo Nordisk.
Quality Center at Lundbeck
For a number of years, Lundbeck had wanted to use a test management system from Hewlett Packard called Quality Center to speed up its IT system testing processes. But the system
had to be validated to ensure it meets regulatory requirements – and this was prohibitively expensive. Until, that is, NNIT offered a version of Quality Center that was prepared for pharmaceutical validation.
According to Mikael Yde, Head of IT compliance in Corporate IT at Lundbeck, the entire process was proving extremely timeconsuming.
“We were running a lot of IT projects, including an SAP implementation,and we were spending a lot of hours on testing. We printed out Word files, and filled in the results in pencil. It worked and we got approval from authorities – but it wasn’t very efficient.”
Lundbeck wanted to implement Quality Center, a test lifecycle management system from Hewlett Packard. But the system was not set up for pharmaceutical companies, and validating it to meet regulatory approval would be expensive. The solution came when NNIT offered a version of Quality Center that was prepared for pharmaceutical validation, which would make the validation process faster. Read the whole Lundbeck story here...
Quality Center at Novo Nordisk
In Novo Nordisk the implementation of Quality Center sped-up the testing procedures in the huge medicinal company with 30 percent.
Novo Nordisk has a number of business critical IT systems – and before new systems or upgrades are rolled-out, they have to be thoroughly tested and all bugs removed.
After working with Quality Center, things looked different:
Pernille Baekgaard, System Manager, who is now responsible for the system at Novo Nordisk, says, “It’s all about time saving – and we’ve seen a significant improvement. It’s hard to know for sure because we didn’t document how long tests took using the old system. But we estimate it’s sped-up our testing procedures by around 30 percent.”
Read the whole story about Novo Nordisk here...